Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Humans
Methotrexate
/ adverse effects
Rituximab
/ adverse effects
Ifosfamide
/ adverse effects
Vincristine
/ adverse effects
Pandemics
Prospective Studies
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Central Nervous System Neoplasms
/ drug therapy
COVID-19
/ etiology
SARS-CoV-2
Cytarabine
/ therapeutic use
Lymphoma
/ etiology
COVID-19
HD-MTX
PCNSL, primary CNS lymphoma
remission induction
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
23
01
2023
received:
16
11
2022
accepted:
27
01
2023
medline:
4
5
2023
pubmed:
11
2
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Clinical data on primary central nervous system (CNS) lymphoma (PCNSL) patients is mostly generated from prospective studies, and many frail real-world patients are not included. Recently,the diagnosis and treatment of PCNSL patients was confounded by the COVID-19 pandemic. In particular, treatment with high-dose cytarabine was linked to increased risk of pneumonia and virus persistence. We report on outcome of the induction regimen R-MIV (rituximab, methotrexate, ifosfamide, and vincristine) involving intensive administration of high-dose methotrexate (3.5 g/m
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Rituximab
4F4X42SYQ6
Ifosfamide
UM20QQM95Y
Vincristine
5J49Q6B70F
Cytarabine
04079A1RDZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
663-672Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM. How we treat primary central nervous system lymphoma. ESMO Open. 2021;6(4):100213.
Graham MS, LM DA. Improving outcomes in primary CNS lymphoma. Best Pract Res Clin Haematol. 2018;31:262-9.
Ferreri AJM., Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international Extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016;3(5):e217-27.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, la Rosée P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international Extranodal lymphoma study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):510-23.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al., IELSG32 study investigators Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 2022;36(7):1870-1878.
Steffanoni S, Calimeri T, Laurenge A, Fox CP, Soussain C, Grommes C, et al. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: a study of the international PCNSL collaborative group. Br J Haematol. 2022;00:1-13.
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarbine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971-9.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015;125(9):1403-10.
Ostrowska B, Osowiecki M, Domanska-Czyz K, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Poplawska L, et al. CHOP-R and high-dose methotrexate in the primary CNS lymphoma revisited. 10-year experience and 92 patients from single institution. Blood. 2013;122(21):3051.
Gupta M, Gupta T, Purandare N, Rangarajan V, Puranik A, Moiyadi A, et al. Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma. CNS Oncol. 2019;8(4):CNS46.
Gupta T, Manjali JJ, Kannan S, Purandare N, Rangarajan V. Diagnostic performance of pretreatment 18F-Fluorodeoxyglucose positron emission tomography with or without computed tomography in patients with primary central nervous system lymphoma: updated systematic review and diagnostic test accuracy meta-analyses. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):497-507.
Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-43.
Zajdel M, Rymkiewicz G, Sromek M, Cieslikowska M, Swoboda P, Kulinczak M, et al. Tumor and cerebrospinal fluid microRNAs in primary central nervous system lymphomas. Cancers (Basel). 2019 Oct 25;11(11):1647.
Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-95.
Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37(10):823-33.
Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061-8.
Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, et al. Rituximab in primary central nervous system lymphoma-a systematic review and meta-analysis. Hematol Oncol. 2019;37(5):548-57.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2019;20(2):216-28.
Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system-an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879-87.